Lee H N, Mahajan M K, Das S, Sachdeva J, Tiwana M S
Dept. of Radiotherapy, Christian Medical College and Hospital, Ludhiana, Punjab 141 008, India.
Dept. of Pathology, Christian Medical College and Hospital, Ludhiana, Punjab 141 008, India.
Gulf J Oncolog. 2015 Jan;1(17):43-51.
The purpose of this prospective study is to understand the early hematological effects of chemo-radiation therapy in cancer patients, their pattern of recovery and to ascertain their prognostic value.
255 diagnosed cancer patients planned for definitive treatment with radiation therapy alone or with chemotherapy were included in this two year prospective study. A complete blood count was done at baseline, weekly during the course of therapy and thereafter, monthly for a period of 6 months. For the purpose of grading clinical toxicity, the Common Toxicity Criteria, CTCAE v2.0 was used while RECIST criteria was used to define the tumor response rates. This study was statistically analyzed using SPSS software.
255 patients were included in the study wherein head and neck cancers comprised the major patient population (28.6%) followed by cervix (18.8%) and breast (15.7%). Out of these, 37% in head-and-neck cancer subgroup, and 58.3% in cervix had anemia at start of treatment. 92.2% cases with chemoradiation developed anemia during treatment, while with radiation alone it was 95.5%. This was statistically significant in patients with cancer uterine cervix (p 〈 0.01). At the end of treatment 65% patients with normal hemoglobin had complete responses (CR), while 58.3% with mild anemia and 33.3% with moderate anemia had CR (p=0.1).
Severe anemia during treatment is a poor prognostic indicator and is usually a sign of advanced disease. Leucopenia and thrombocytopenia occur more commonly during chemoradiotherapy as against radiotherapy alone, but improves with supportive management.
本前瞻性研究的目的是了解放化疗对癌症患者早期血液学的影响、恢复模式,并确定其预后价值。
本为期两年的前瞻性研究纳入了255例计划接受单纯放疗或化疗的确诊癌症患者。在基线时、治疗期间每周以及此后6个月每月进行一次全血细胞计数。为了对临床毒性进行分级,使用了通用毒性标准(CTCAE v2.0),而使用RECIST标准来定义肿瘤反应率。本研究使用SPSS软件进行统计分析。
255例患者纳入研究,其中头颈部癌症患者占主要人群(28.6%),其次是子宫颈癌(18.8%)和乳腺癌(15.7%)。其中,头颈部癌症亚组中37%、子宫颈癌中58.3%的患者在治疗开始时患有贫血。92.2%接受放化疗的患者在治疗期间出现贫血,而单纯放疗患者为95.5%。这在子宫颈癌患者中具有统计学意义(p〈0.01)。治疗结束时,血红蛋白正常的患者中有65%达到完全缓解(CR),而轻度贫血患者中有58.3%、中度贫血患者中有33.3%达到CR(p = 0.1)。
治疗期间的严重贫血是不良预后指标,通常是疾病进展的标志。与单纯放疗相比,放化疗期间白细胞减少和血小板减少更常见,但通过支持治疗可改善。